27758943|t|Renal Function and the Risk of Stroke and Bleeding in Patients With Atrial Fibrillation: An Observational Cohort Study
27758943|a|We sought to determine the risk of stroke / thromboembolism and bleeding associated with reduced renal function in patients with atrial fibrillation and the risk of stroke and bleeding associated with warfarin treatment in specific estimated glomerular filtration rate (eGFR) groups. We conducted a register-based cohort study and included patients discharged with nonvalvular atrial fibrillation from 1997 to 2011 with available eGFR. A total of 17 349 patients were identified with eGFR available at baseline. All levels of lower eGFR were associated with higher risk of stroke / thromboembolism and bleeding. Use of warfarin was associated with higher bleeding risk in all eGFR groups; hazard ratios 1.23 (95% confidence interval [CI], 0.97-1.56), 1.26 (95% CI, 1.14-1.40), 1.18 (95% CI, 1.07-1.31), 1.11 (95% CI, 0.87-1.42), 2.01 (95% CI, 1.14-3.54) in patients with eGFR ≥90, 60 to 89, 30 to 59, 15 to 29, and <15 mL/min per 1.73 m(2), respectively. Use of warfarin was associated with lower risk of stroke / thromboembolism in patients with eGFR ≥15 mL/min per 1.73 m(2); hazard ratios 0.57 (95% CI, 0.43-0.76), 0.57 (95% CI, 0.51-0.64), 0.48 (95% CI, 0.44-0.54), 0.60 (95% CI, 0.45-0.80) in patients with eGFR ≥90, 60 to 89, 30 to 59, and 15 to 29 mL/min per 1.73 m(2), respectively. Use of warfarin was not associated with lower risk of stroke / thromboembolism in patients with eGFR <15 mL/min per 1.73 m(2); hazard ratio 1.18 (95% CI, 0.58-2.40). In patients with atrial fibrillation, the risk of stroke and bleeding was associated with levels of renal function. Warfarin treatment was associated with higher risk of bleeding in all eGFR groups and lower risk of stroke in patients with eGFR ≥15 mL/min per 1.73 m(2).
27758943	0	14	Renal Function	T038	UMLS:C0232804
27758943	31	37	Stroke	T038	UMLS:C0038454
27758943	42	50	Bleeding	T038	UMLS:C0019080
27758943	68	87	Atrial Fibrillation	T038	UMLS:C0004238
27758943	154	160	stroke	T038	UMLS:C0038454
27758943	163	178	thromboembolism	T038	UMLS:C0040038
27758943	183	191	bleeding	T038	UMLS:C0019080
27758943	216	230	renal function	T038	UMLS:C0232804
27758943	248	267	atrial fibrillation	T038	UMLS:C0004238
27758943	284	290	stroke	T038	UMLS:C0038454
27758943	295	303	bleeding	T038	UMLS:C0019080
27758943	351	387	estimated glomerular filtration rate	T058	UMLS:C3811844
27758943	389	393	eGFR	T058	UMLS:C3811844
27758943	484	515	nonvalvular atrial fibrillation	T038	UMLS:C0004238
27758943	549	553	eGFR	T058	UMLS:C3811844
27758943	603	607	eGFR	T058	UMLS:C3811844
27758943	651	655	eGFR	T058	UMLS:C3811844
27758943	692	698	stroke	T038	UMLS:C0038454
27758943	701	716	thromboembolism	T038	UMLS:C0040038
27758943	721	729	bleeding	T038	UMLS:C0019080
27758943	738	746	warfarin	T103	UMLS:C0043031
27758943	774	782	bleeding	T038	UMLS:C0019080
27758943	795	799	eGFR	T058	UMLS:C3811844
27758943	990	994	eGFR	T058	UMLS:C3811844
27758943	1081	1089	warfarin	T103	UMLS:C0043031
27758943	1124	1130	stroke	T038	UMLS:C0038454
27758943	1133	1148	thromboembolism	T038	UMLS:C0040038
27758943	1166	1170	eGFR	T058	UMLS:C3811844
27758943	1331	1335	eGFR	T058	UMLS:C3811844
27758943	1417	1425	warfarin	T103	UMLS:C0043031
27758943	1464	1470	stroke	T038	UMLS:C0038454
27758943	1473	1488	thromboembolism	T038	UMLS:C0040038
27758943	1506	1510	eGFR	T058	UMLS:C3811844
27758943	1593	1612	atrial fibrillation	T038	UMLS:C0004238
27758943	1626	1632	stroke	T038	UMLS:C0038454
27758943	1637	1645	bleeding	T038	UMLS:C0019080
27758943	1676	1690	renal function	T038	UMLS:C0232804
27758943	1746	1754	bleeding	T038	UMLS:C0019080
27758943	1762	1766	eGFR	T058	UMLS:C3811844
27758943	1792	1798	stroke	T038	UMLS:C0038454
27758943	1816	1820	eGFR	T058	UMLS:C3811844